For its second fiscal quarter (ending June 30), Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has reported E.P.S. of $-0.08 compared to $0.03 a year ago. E.P.S. were $-0.19 for the latest four quarters through June 30 versus $0.26 for the same period a year ago.
Recent Price Action
On 7/31/24, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) stock was unchanged 0.0%, closing at $5.84. However, trading volume in this flat performance was unusually low at 59% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -7.3% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, VNDA is expected to be Value Creation neutral.
Vanda Pharmaceuticals has a current Value Trend Rating of A (Highest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. Vanda Pharmaceuticals has a slightly positive Appreciation Score of 64 and a very high Power Rating of 89, with the Highest Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment